texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Austin North Research and Clinical Trials

Texas Oncology-Austin North participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin North Suite 120 (Expand)

Carcinoid

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Endometrial Cancer

Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy (KRT-232-118) Read Moreabout Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

Phase: II/III

Ph2 Girdes Endo Carcinoma

A PHASE II SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195) Read Moreabout Ph2 Girdes Endo Carcinoma

Phase: II

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

Fallopian Tube Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Ovarian Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Peritoneal Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Uterine Cancer

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Texas Oncology-Austin North Suite 300 (Expand)

Carcinoid

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Endometrial Cancer

Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy (KRT-232-118) Read Moreabout Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

Phase: II/III

Ph2 Girdes Endo Carcinoma

A PHASE II SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195) Read Moreabout Ph2 Girdes Endo Carcinoma

Phase: II

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

Fallopian Tube Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Ovarian Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Peritoneal Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Uterine Cancer

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II